Fletcher Paul J, Rizos Zoë, Sinyard Judy, Tampakeras Maria, Higgins Guy A
Section of Biopsychology, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Neuropsychopharmacology. 2008 May;33(6):1402-12. doi: 10.1038/sj.npp.1301509. Epub 2007 Jul 25.
Previously, we showed that the 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration, and the ability of cocaine to reinstate responding after extinction of drug-seeking behavior. The present experiments extended these findings further by determining whether the effects of Ro60-0175 on self-administration were sustained with repeated treatment, and whether Ro60-0175 altered reinstatement induced by the pharmacological stressor yohimbine, or by the context in which self-administration occurred. In Experiment 1, Ro60-0175 (1 mg/kg, s.c.) reduced cocaine (0.25 mg/infusion) self-administration maintained by a progressive ratio schedule. This reduction was sustained over eight daily injections. In Experiment 2, rats self-administered cocaine in daily 2 h sessions for 15 days on a FR1 schedule. Following extinction, yohimbine (1 mg/kg, i.p.) reinstated responding, and this effect was reduced dose dependently by Ro60-0175 (0.3-3 mg/kg, s.c.). In Experiment 3, rats were trained to respond for cocaine on a FR1 schedule in a distinct environmental context (A); responding was then extinguished in a different context (B). Reinstatement tests occurred in either context A or B. Responding was reinstated only when rats were tested in the original self-administration context (A). This reinstatement was reduced dose dependently by Ro60-0175. All effects of Ro60-0175 were blocked by the 5-HT2C receptor antagonist SB242084. Thus, Ro60-0175, acting via 5-HT2C receptors, reduces cocaine self-administration and cocaine-seeking triggered by a stressor and by drug-associated cues. The effects of Ro60-0175 do not exhibit tolerance within the 8-day test period. These results indicate that selective 5-HT2C receptor agonists may be a useful pharmacological strategy for treatment of drug abuse.
此前,我们发现5-羟色胺2C(5-HT2C)受体激动剂Ro60-0175可减少可卡因的自我给药行为,以及可卡因在觅药行为消退后恢复反应的能力。本实验通过确定Ro60-0175对自我给药行为的影响在重复给药后是否持续,以及Ro60-0175是否改变了由药理应激剂育亨宾或自我给药发生的环境所诱导的恢复反应,进一步扩展了这些发现。在实验1中,Ro60-0175(1毫克/千克,皮下注射)减少了通过累进比率程序维持的可卡因(0.25毫克/注射)自我给药行为。这种减少在每日八次注射中持续存在。在实验2中,大鼠在FR1程序下每天进行2小时的可卡因自我给药,持续15天。消退后,育亨宾(1毫克/千克,腹腔注射)恢复了反应,并且这种效应被Ro60-0175(0.3 - 3毫克/千克,皮下注射)剂量依赖性地降低。在实验3中,大鼠在一个独特的环境背景(A)下接受FR1程序的可卡因反应训练;然后在不同的背景(B)下使反应消退。恢复测试在背景A或B中进行。只有当大鼠在原来的自我给药背景(A)中进行测试时,反应才会恢复。这种恢复被Ro60-0175剂量依赖性地降低。Ro60-0175的所有效应都被5-HT2C受体拮抗剂SB242084阻断。因此,通过5-HT2C受体起作用的Ro60-0175可减少可卡因的自我给药行为以及由应激源和与药物相关的线索引发的觅药行为。Ro60-0175的效应在8天的测试期内未表现出耐受性。这些结果表明,选择性5-HT2C受体激动剂可能是治疗药物滥用的一种有用的药理学策略。